The repeating unit of the C. difficile Toxin A (rARU, also known as CROPS [combined repetitive oligopeptides]) C-terminal region, was shown to elicit protective immunity against C. difficile and is under consideration as a possible vaccine against this pathogen. However, expression of recombinant rARU in E. coli using the standard vaccine production process was very low. Transcriptome and proteome analyses showed that at restricted dissolved oxygen (DO) the numbers of differentially expressed genes (DEGs) was 2.5-times lower than those expressed at unrestricted oxygen. Additionally, a 7.4-times smaller number of ribosome formation genes (needed for translation) were down-regulated as compared with unrestricted DO. Higher rARU expression at restricted DO was associated with up-regulation of 24 heat shock chaperones involved in protein folding and with the up-regulation of the global regulator RNA chaperone hfq. Cellular stress response leading to down-regulation of transcription, translation, and energy generating pathways at unrestricted DO were associated with lower rARU expression. Investigation of the C. difficile DNA sequence revealed the presence of cell wall binding profiles, which based on structural similarity prediction by BLASTp, can possibly interact with cellular proteins of E. coli such as the transcriptional repressor ulaR, and the ankyrins repeat proteins. At restricted DO, rARU mRNA was 5-fold higher and the protein expression 27-fold higher compared with unrestricted DO. The report shows a strategy for improved production of C. difficile vaccine candidate in E. coli by using restricted DO growth. This strategy could improve the expression of recombinant proteins from anaerobic origin or those with cell wall binding profiles.Clostridium difficile (C. difficile) is an anaerobic bacterial pathogen responsible for diarrhea and pseudomembranous colitis 1,2 . The bacteria produces two high molecular weight toxins, toxin A (308 kDa) and toxin B (269 kDa) 3,4 ; both contain a repeating region called rARU (CROPs) (104 kDa) in subunit A and rBRU (70 kDa) in subunit B 5,6 . Both Toxin A and Toxin B are responsible for clinical symptoms and are candidates for vaccine development 7,8 . Pfizer's genetically detoxified vaccine against C difficile is a toxoid mix of Toxin A and Toxin B expressed recombinantly is about to enter clinical trial phase III, and Valneva has a vaccine candidate of recombinant fusion protein of truncated portions of Toxin A and Toxin B, which completed a clinical trial phase II, with promising results 9-12 .In this report, we focused on improving the expression of the repeating unit region (rARU) of the C. difficile toxin A. The importance of rARU was shown in animal models where serum neutralizing antibodies to toxin A conferred immunity to this pathogen and antiserum against nontoxic recombinant peptide, containing the www.nature.com/scientificreports www.nature.com/scientificreports/ repeating units region (rARU), neutralized the enterotoxic and cytotoxic activity of the toxin 13,14 ...